Human BioSystems
OTC Bulletin Board : HBSC

Human BioSystems

January 29, 2007 07:01 ET

HBS BioEnergy Strengthens Management Team - Appoints COO and Financial Advisor for Ethanol Projects

PALO ALTO, CALIFORNIA--(CCNMatthews - Jan. 29, 2007) - (OTCBB:HBSC) - Human BioSystems ("HBS") announced today that HBS BioEnergy ("HBSE"), a wholly owned subsidiary of HBS, has strengthened its management team by enlisting the services of two veteran bio-fuels professionals.

Mr. Claude Luster III, President and Primary Technologist of HBS BioEnergy has appointed Mr. Michael Schnepp as HBSE's Chief Operating Officer. "Mr. Schnepp has worked in the ethanol and biodiesel industry for the past 21 years in project development, production management, maintenance and construction, operations, operator training and plant start-ups for 6 ethanol facilities," stated Mr. Luster. "He brings a wealth of direct experience and knowledge in analyzing, building and managing bio-fuels plants that should have a direct contribution and impact on our projects," continued Mr. Luster.

Some of Mr. Schnepp's accomplishments include the following:

1. Assisted with the development of an 80 million gallon/year ethanol facility in the Pacific Northwest and a 15 million gallon/year ethanol facility in British Columbia.

2. Co-founded an 80 million gallon/year ethanol facility in Clatskanie, Oregon which involved site evaluation, and site selection.

3. Responsible for relocating a 30 million gallon/year ethanol facility in Jasper, Tennessee to Hasting, Nebraska which involved numerous logistics and technical issues.

4. Provided consulting services to owners, managers and constructors of renewable energy projects.

HBS BioEnergy also contracted the services of Mr. Thomas Byrne as its Financial Advisor through his own consulting firm of Byrne & Company Limited, which assists companies with their project and organizational requirements. Mr. Byrne has been engaged by HBSE to develop financial models and business plans for bio-fuels projects that HBSE considers viable.

Mr. Byrne has completed numerous financial models and business plans for ethanol and bio-fuels projects that have received funding. He is a Certified Public Accountant, a Certified Economic Development Financing Professional and holds memberships in a number of professional organizations including the Renewable Fuels Association.

"The fuel ethanol and biodiesel market in the U.S. is currently limited only by the supply of available product," stated Mr. Luster. Approximately 5 billion gallons of ethanol were produced in the U.S. in 2006. The Renewable Fuels Standard (RFS) which was established under the Energy Policy Act of 2005, calls for 7 billion gallons per year of ethanol and bio-diesel combined by 2012.

Under the proposed Biofuels Security Act of 2007, an amplified RFS benchmark of 30 billion gallons per year by 2020 and 60 billion gallons per year by 2030 for ethanol and biodiesel use has been set.

"This can be a significant opportunity for us if we can take advantage of the increasing use of biofuels" concluded Mr. Luster.

HBS BioEnergy is planning to develop potential sites to produce ethanol and biodiesel fuels for the U.S. market. The company has offices in Fresno, California.

Certain statements contained herein are "forward-looking" statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, failure to obtain regulatory approvals for the construction of ethanol plants, failure to obtain the required financing and to construct the ethanol plants, failure of the ethanol plants to meet standards, the inability to find raw material for the production of ethanol or to sell the ethanol at on acceptable terms, the risks involved in pursuing a business unrelated to HBS' prior business, and other factors discussed in filings made by the Company with the Securities and Exchange Commission.

Contact Information

  • Human BioSystems
    Harry Masuda
    (650) 323-0943
    or
    Yes International
    Investor Relations
    1-800-631-8127